

2012 International Pharmaceutical Statistics Workshop (IPSW) July 10 – July 12, 2012 • Shanghai • China

Third Announcement (May, 2012)

The growing trend of global clinical drug development demands increasing number of biometrics-related professionals (biostatisticians, clinical programmers and clinical database professional) across the globe. This trend is most noticeably reflected in the establishment of biometrics centers in China by world's major pharmaceutical companies, and newly established division of biostatistics in the SFDA.

To promote biopharmaceutical statistics education and profession, the 2012 International Pharmaceutical Statistics Workshop (IPSW) will be hosted by Academy of Applied Statistical Science, East China Normal University (ECNU) and Shanghai Biostatistics Forum (SBF) from July 10 to July 12, 2012.

Other institutional sponsors for this event include:

China Applied Statistics Association, Survival Analysis Society
Duke University, Department of Biostatistics and Bioinformatics
Hong Kong Baptist University, Statistics Research and Consultancy Centre
International Chinese Statistical Association
International Society of Biopharmaceutical Statistics
Shanghai Institute of Pharmaceutical Industry
University of Wisconsin-Madison, Department of Statistics

For updated information, please visit workshop website: <http://www.sfs.ecnu.edu.cn/2012IPSW/IPSW2012.html>.

2012 International Pharmaceutical Statistics Workshop (IPSW)
July 10 – July 12, 2012 • Shanghai • China

Invited Keynote Speakers

- Dr Michael Kosorok Professor and Chair, Department of Biostatistics, University of North Carolina at Chapel Hill
Dr Bob O'Neill Director, Office of Biostatistics, CDER, FDA

Invited Speakers (partial list)

- Dr Frank Bretz Global Head of Statistical Methodology, Novartis Pharma AG and Adjunct Professors at Hannover Medical School and SHUFE
Dr Ivan S.F. Chan Senior Director, Late Development Statistics, Merck & Co, Inc. and President, International Chinese Statistical Association
Dr Shein-Chung Chow Professor, Department of Biostatistics, Duke University
Dr Chinfu Hsiao Director, Clinical Trial Center, National Health Research Institutes, Taiwan
Dr Chao Agnes Hsiung Distinguished Investigator and Director, Division of Biostatistics and Bioinformatics, National Health Research Institutes, Taiwan
Dr Byron Jones Biometrical Fellow, Novartis Pharma AG and Visiting Professor of Statistics at University College London
Dr Gordon Lan Senior Director of QDS, Janssen R&D, Johnson & Johnson
Dr Guohua Pan Director, Clinical Biostatistics, Janssen R&D, Johnson & Johnson
Dr Claude Petit Executive Director of Biostatistics, Boehringer Ingelheim, USA
Dr Stephen Ruberg Distinguished Research Fellow, Eli Lilly and Company
Dr Stephen Senn Head of Unit, Competence Center for Methodology and Statistics, CRP-Santé, Luxembourg
Dr Yi Tsong Deputy Director of Division of Biometrics VI, CDER, FDA
Dr Yue Wang Head of Quantitative Biology, BeiGene
Dr Jielai Xia Professor, The Fourth Military Medical University
Dr Chen Yao Professor and Head of Department of Biostatistics, Peking University First Hospital
Dr Kwee Poo Yeo Senior Research Scientist, Eli Lilly and Company
Dr Heping Zhang Professor, School of Public Health, Yale University
Dr Peng-Liang Zhao Head of Biostatistics & Programming in China, Sanofi
Dr Bob Zhong Associate Director, Janssen R&D, Johnson & Johnson



2012 International Pharmaceutical Statistics Workshop (IPSW) July 10 – July 12, 2012 • Shanghai • China

Program

Short Courses (July 10, 2012)

- SC-I 'Adaptive design'
Dr Shein-Chung Chow, Professor, Department of Biostatistics and Bioinformatics, Duke University
- SC-II 'Non-inferiority trial'
Dr Yi Tsong, CDER, FDA
- SC-III 'Meta analysis'
Dr Byron Jones, Biometrical Fellow, Novartis Pharma AG

Workshop (July 11 – July 12, 2012)

Sessions

- Survival trial and oncology
- Early development and genetic statistics
- Personalized medicine and biomarker
- Biosimilarity
- Noninferiority trial
- Adaptive design
- Statistical programming
- Clinical data management
- Multi-regional clinical trial
- Pharamco-vigillance and pharmaco-epidemiology
- Bayes statistics and medical device
- Independent data monitoring committee
- Regulatory statistics (panel discussion)
- Biostatistics education and career promotion (panel discussion)

2012 International Pharmaceutical Statistics Workshop (IPSW) July 10 – July 12, 2012 • Shanghai • China

Venue

Jianguo Hotel Shanghai (439 North Caoxi Road, Shanghai 200030) www.jianguo.com

Registration

Domestic attendees: please send the *registration form* to ipsw2012@gmail.com
and send the *hotel reservation form* to simongaolei@yahoo.com.cn
International attendees: please register at www.isbiostat.org/ipsw2012/

Fee schedule

Domestic	Before May 1, 2012		On/After May 1, 2012	
	Short Courses (July 10, 2012)			
	Half day	Full day	Half day	Full day
Student	250RMB	400RMB	300RMB	500RMB
Non-student	500RMB	800RMB	600RMB	1000RMB
Fees include tea break.				
Workshop (July 11-12, 2012)				
Student	500RMB		600RMB	
Non-student	1000RMB		1200RMB	
Fees include tea break, lunch buffet, and banquet. 200RMB/additional guest for banquet				
International	Before May 1, 2012		On/After May 1, 2012	
	Short Courses (July 10, 2012)			
	Half day	Full day	Half day	Full day
Student	50USD	80USD	60USD	100USD
Non-student	100USD	160USD	120USD	200USD
Fees include tea break.				
Workshop (July 11-12, 2012)				
Student	100USD		120USD	
Non-student	200USD		240USD	
Fees include tea break, lunch buffet, and banquet. 40USD/additional guest for banquet				

Cancellations Policy:

All cancellations must be submitted in writing through email: ipsw2012@isbiostat.org (for international) and ipsw2012@gmail.com (for domestic). Cancellation received on/before June 9, 2012: Conference registration will be refunded less a \$20 (130RMB for domestic) processing fee. Short courses will be refunded less \$20 (130RMB for domestic) per course. Cancellations received after June 9, 2012 but on/before July 1: 50% of registration fee for the conference and the short courses will be refunded. Cancellations received after July 1: No refund will be issued. Registrants who do not submit cancellation on or before July 1 will be responsible for the full registration fee. Registrants are responsible for cancelling their own hotel reservations. If the event is cancelled, the organization is not responsible for airfare, hotel or other costs incurred by the registrant.



2012 International Pharmaceutical Statistics Workshop (IPSW)
July 10 – July 12, 2012 • Shanghai • China

Steering committee:

Shein-Chung Chow (Duke)
Qin Huang (SFDA)
Jun Shao (ECNU)
William Wang (Merck)
Naiqing Zhao (Fudan)

Program committee:

Co-chairs:

Jun Shao (ECNU), William Wang (Merck), Naiqing Zhao (Fudan)

Committee Members:

Shein-Chung Chow (Duke)
Jia He (SMMU)
Xiaoyin Fan (Vertex)
Jacqueline Law (Roche)
Minzhi Liu (MacroStat)
Changxuan Mao (SHUFE)
Robert Luo (Pfizer)
Dejun Tang (Novartis)
Wenjin Wang (Pfizer)
Jin Xu (ECNU)
Chen Yao (PKU)
Bingming Yi (GSK)
Weiyong Yuan (Johnson & Johnson)
Wei Zhang (Boehringer Ingelheim)
Shuping Zhang (Merck)
Zibao Zhang (PPD)
Pengliang Zhao (Sanofi-Aventis)

Local Organizing Committee:

Jun Shao (ECNU)
Naiqing Zhao (Fudan)
Jin Xu (ECNU)
Yingchun Zhou (ECNU)
Hekun Xu (ECNU)

Contact us

Address: Academy of Applied Statistical Science, East China Normal University, 500 Dongchuan Road, Shanghai 200241
Email: ipsw2012@gmail.com; yczhou@stat.ecnu.edu.cn (Dr Yingchun Zhou)
Tel/Fax: 86-21-54345058

2012 International Pharmaceutical Statistics Workshop (IPSW)
July 10 – July 12, 2012 • Shanghai • China

Program Outline

Day One: Tuesday, July 10, 2012			
8:00 – 21:00	Registration		
8:30 – 12:00	Short Course I: Adaptive design Dr Shein-Chung Chow, Duke University		
12:00 – 13:30	Luncheon		
14:00 – 17:30	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%;">Short Course II: Non-inferiority trial Dr Yi Tsong, CDER, FDA</td> <td style="width: 50%;">Short Course III: Meta analysis Dr Byron Jones, Novartis</td> </tr> </table>	Short Course II: Non-inferiority trial Dr Yi Tsong, CDER, FDA	Short Course III: Meta analysis Dr Byron Jones, Novartis
Short Course II: Non-inferiority trial Dr Yi Tsong, CDER, FDA	Short Course III: Meta analysis Dr Byron Jones, Novartis		

Day Two: Wednesday, July 11, 2012			
8:00 – 11:30	Registration		
8:30 - 9:00	Opening Remarks		
9:00 – 10:00	<p>Plenary-I: The Science of Regulatory Statistics: A Perspective on its Growth and Impact Organizer and Chair: Shein-Chung Chow (Duke) Bob O’Neill (FDA)</p>		
10:00 – 10:20	Tea Break		
10:20 – 11:50	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <p>Parallel 1: Biosimilarity Organizers and Chairs: Shein-Chung Chow (Duke)</p> <ul style="list-style-type: none"> • Regulatory requirements for assessment of biosimilar products – Dr Chinfu Hsiao, Director, Clinical Trial Center, National Health Research Institutes, Taiwan • Some statistical issues on the evaluation of the similarity and interchangeability of biologics – Dr Laszlo Endrenyi, U. of Toronto • Scientific factors for assessing biosimilarity and interchangeability of follow-on biologics – Dr Shein-Chung Chow, Professor, Duke U. </td> <td style="width: 50%; vertical-align: top;"> <p>Parallel 2: IDMC Organizers and Chairs: Irving Hwang (ICG), Yingchun Zhou (ECNU)</p> <ul style="list-style-type: none"> • Interim analysis and design of clinical trials – Dr Kuang-Kuo Gordon Lan, Senior Director, Janssen R&D, Johnson & Johnson, • Experience in multicenter oncology trials in Taiwan – Dr Chao Agnes Hsiung, National Health Research Institute, Taiwan • Practice of DMCs in clinical trials in China – Dr Chen Yao, Professor, Peking University Clinical Research Institute </td> </tr> </table>	<p>Parallel 1: Biosimilarity Organizers and Chairs: Shein-Chung Chow (Duke)</p> <ul style="list-style-type: none"> • Regulatory requirements for assessment of biosimilar products – Dr Chinfu Hsiao, Director, Clinical Trial Center, National Health Research Institutes, Taiwan • Some statistical issues on the evaluation of the similarity and interchangeability of biologics – Dr Laszlo Endrenyi, U. of Toronto • Scientific factors for assessing biosimilarity and interchangeability of follow-on biologics – Dr Shein-Chung Chow, Professor, Duke U. 	<p>Parallel 2: IDMC Organizers and Chairs: Irving Hwang (ICG), Yingchun Zhou (ECNU)</p> <ul style="list-style-type: none"> • Interim analysis and design of clinical trials – Dr Kuang-Kuo Gordon Lan, Senior Director, Janssen R&D, Johnson & Johnson, • Experience in multicenter oncology trials in Taiwan – Dr Chao Agnes Hsiung, National Health Research Institute, Taiwan • Practice of DMCs in clinical trials in China – Dr Chen Yao, Professor, Peking University Clinical Research Institute
<p>Parallel 1: Biosimilarity Organizers and Chairs: Shein-Chung Chow (Duke)</p> <ul style="list-style-type: none"> • Regulatory requirements for assessment of biosimilar products – Dr Chinfu Hsiao, Director, Clinical Trial Center, National Health Research Institutes, Taiwan • Some statistical issues on the evaluation of the similarity and interchangeability of biologics – Dr Laszlo Endrenyi, U. of Toronto • Scientific factors for assessing biosimilarity and interchangeability of follow-on biologics – Dr Shein-Chung Chow, Professor, Duke U. 	<p>Parallel 2: IDMC Organizers and Chairs: Irving Hwang (ICG), Yingchun Zhou (ECNU)</p> <ul style="list-style-type: none"> • Interim analysis and design of clinical trials – Dr Kuang-Kuo Gordon Lan, Senior Director, Janssen R&D, Johnson & Johnson, • Experience in multicenter oncology trials in Taiwan – Dr Chao Agnes Hsiung, National Health Research Institute, Taiwan • Practice of DMCs in clinical trials in China – Dr Chen Yao, Professor, Peking University Clinical Research Institute 		
12:00 – 13:30	Luncheon		

2012 International Pharmaceutical Statistics Workshop (IPSW)
July 10 – July 12, 2012 • Shanghai • China

Day Two: Wednesday, July 11, 2012		
13:30 – 15:00	<p>Parallel 3: Personalized medicine and biomarker Organizer and Chair: Robert Luo (Pfizer), Minzhi Liu (MacroStat)</p> <ul style="list-style-type: none"> Statistical considerations during the discovery and development of patient selection biomarkers – Dr Yue Wang, Head of Quantitative Biology, BeiGene Finding the right patients considerations for developing tailored therapeutics – Dr Steven J. Ruberg, Distinguished Research Fellow, Eli Lilly & Company Zelboraf for unresectable or metastatic melanoma with the BRAF V600 mutation: Clinical development of a targeted therapy – Betty Nelson, Principal Statistical Scientist, Roche/Genentech 	<p>Parallel 4: Decision-making and scientific programming Organizer and Chair: Shuping Zhang (Merck)</p> <ul style="list-style-type: none"> Decision-making in post clinical trials – Dr Heping Zhang, Professor, Yale University Alternative imputation method using SAS – Dr Xingshu Zhu, Merck Inc. Collaboration between China and Japanese pharmaceutical industry – Dr Masato Suzuke, Japan Merck – KK
15:00 – 15:20	Tea Break	
15:20 – 16:50	<p>Parallel 5: Early development statistics Organizer and Chair: Bingming Yi (GSK)</p> <ul style="list-style-type: none"> Statisticians and pharmacological modellers: collaboration is the key to success – Dr Stephen Senn, Head of Unit, Competence Center for Methodology and Statistics, CRP-Santé, Luxembourg Critical success factors for early phase drug development – Dr Kwee Poo YEO, Senior Research Scientist, Eli Lilly and Company On the time to conclusion of Phase II cancer clinical trials and its application in trial designs – Dr Ying Lu, Professor, Stanford University 	<p>Parallel 6: Clinical data management Organizers and Chairs: Zibao Zhang (PPD)</p> <ul style="list-style-type: none"> China clinical data management regulatory updates – Dr Qin Huang, Office of Biostatistics, China SFDA/CDE CDM role in the FDA guidance of risk-based approach to monitoring – Joan Huang, Clinical Data Service, Pfizer CRDC Opportunities and challenges in clinical data management – Robert Robinson, Life Sciences BPO – China Cognizant

2012 International Pharmaceutical Statistics Workshop (IPSW)
July 10 – July 12, 2012 • Shanghai • China

17:00 – 18:30 (refreshment served)	Panel discussion: Regulatory statistics Organizer and Chair: Bill Wang (Merck) Qin Huang (SFDA), Bob O'Neill (FDA), Yi Tsong (FDA), Chen Yao (PKU), Toshimitsu Hamasaki (Osaka U), Shein-Chung Chow (Duke)
18:30- 20:00	Banquet

Day Three: Thursday, July 12, 2012	
8:30 – 10:00	<p>Parallel 7: Survival trial and Oncology Organizer and Chair: Weiyang Yuan (J&J), Changxuan Mao (SHUFE)</p> <ul style="list-style-type: none"> Survival data analysis – Kuang-Kuo Gordon Lan, Senior Director, Janssen R&D, Johnson & Johnson Analyses of time-to-event data in the NDA of Rivaroxaban for atrial fibrillation – Dr Guohua (James) Pan, Director, Janssen R&D, Johnson & Johnson Statistical Power in Stratified or Covariate-Adjusted Failure Time Data Analyses – Dr Jianliang Zhang, MedImmune
	<p>Parallel 8: Adaptive design Organizer and Chair: Jin Xu (ECNU) and Linda Sun (Merck)</p> <ul style="list-style-type: none"> On the efficiency of two-stage response-adaptive – Dr Frank Brets, Novartis The advantageous adaptive randomization in clinical trials – Dr Bob Zhong, Janssen Pharmaceuticals, Johnson & Johnson Improving vaccine clinical development using adaptive design strategies – Dr Ivan S.F. Chan, Senior director, Merck
10:00 – 10:20	Tea Break
10:20 – 11:50	<p>Parallel 9: Non-inferiority trial Organizer and Chair: Wei Zhang (BI) and Jia He (SMMU)</p> <ul style="list-style-type: none"> Comparing the response rates for superiority, non-inferiority and equivalence testing with multiple-to-one matched binary endpoint – Yi Tsong, CDER, FDA What did we learn from the most recent FDA advisory committees when reviewing non inferiority trials? – Claude Petit, Boehringer Ingelheim The statistical consensus of non-inferiority clinical trial for NDA in China – Jielai Xia, The 4th Military Medical U.
	<p>Parallel 10: Bayes statistics and Medical device Organizer and Chair: Dejun Tang (Novartis)</p> <ul style="list-style-type: none"> Examples of the use of Bayesian methods in the pharmaceutical industry – Dr Byron Jones, Novartis Pharma AG Bayesian adaptive designs for early-phase oncology trials – Dr Guosheng Yin, HongKong U. Bayesian applications in medical regulations in the US – Yao Huang, FDA
12:00 – 13:30	Luncheon

2012 International Pharmaceutical Statistics Workshop (IPSW)
July 10 – July 12, 2012 • Shanghai • China

Day Three: Thursday, July 12, 2012	
13:30 – 15:00	<p>Parallel 11: Multi-regional clinical trial Organizer and Chair: Pengliang Zhao (Sanofi), Jacqueline Law (Roche)</p> <ul style="list-style-type: none"> Design considerations for simultaneous global drug development – Dr Gang Chen, Johnson and Johnson Practical issues and lessons learned from HERA and ToGA trials conducted in Japan as part of multi-regional Clinical Trials – Hideharu Yamamoto, Chugai Pharmaceutical Empirical shrinkage estimator for consistency assessment of treatment effects in multi-regional clinical trials – Dr Peng-Liang Zhao, Sanofi
13:30 – 15:00	<p>Parallel 12: Pharamco-vigillance and Pharmaco-epidemiology Organizer and Chair: Wei Zhou (Merck) Bill Wang (Merck)</p> <ul style="list-style-type: none"> Pharmacoepidemiology perspectives of CER – Dr Jay Pearson, Merck Prior event rate ratio (PERR) adjustment for unrecognized confounding in observational studies – Dr Menggang Yu, U. of Wisconsin-Madison Sequential generalized likelihood ratio tests for safety evaluation – Dr Jie Chen, Merck Serono
15:00 – 15:20	Tea Break
15:20 – 16:20	<p>Plenary-II: Personalized Medicine and Statistical Learning Organizers: Jun Shao (ECNU) Michael Kosorok (Department of Biostatistics, UNC)</p>
16:30 – 18:00 (refreshment served)	<p>Panel discussion: Biostatistics education and career promotion Organizers: Naiqing Zhao (Fudan) and Jin Xu (ECNU) Michael Kosorok (UNC), Ivan S. F. Chan (Merck), Stephen Senn, Jun Shao (ECNU),</p>
18:00 – 18:05	Closing Remarks